T cells

[Oncotelic Therapeutics, Inc.] Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.

[G1 Therapeutics, Inc.] G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.

[Cell Stem Cell] The authors reported an analysis on one year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen.

[Nature Communications] Investigators found that the core microRNA biogenesis and targeting machinery maintained the sensitivity of cancer cells to PD-1-independent T cell-mediated cytotoxicity.

[Breast Cancer Research and Treatment] Breast cancer is immunogenic and a variety of vaccines have been designed to boost immunity directed against the disease. Newer approaches are designing vaccines to prevent breast cancer by intercepting high-risk lesions such as ductal carcinoma in situ to limit the progression of these tumors to invasive cancer.

[Human Immunology] The authors reviewed the molecular mechanisms and the role of immune cells and responses involved in pulmonary hypertension development.